This site uses cookies. By using this site you agree to receiving cookies. View Policy.
/https://files-crowdcube-com.s3.amazonaws.com/files/pitch_pics/original/201903/blob_e99d4b6330627094077d6a7eab99aa77)
REPLICATE is here to change single tooth replacement with a patented, patient-friendly product that does not require drilling or destroying healthy teeth. Focus is the £18 billion tooth replacement market in the USA. Clinically validated in Europe, U.S. FDA filings are complete, awaiting approval.
- Unique, disruptive approach to single tooth replacement
- Raised over £17M from founders, VCs and crowd investors
- Clearance to sell in the EU
- Founders are serial entrepreneurs, sold last dental company to 3M
Idea
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201906/a1b172cce50c62cc9f85ba5acf9ba83b.jpg)
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201906/f14cf82ca36dcee8069a8ce43a8e3ce3.jpg)
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201906/2831210cad4de06d49227c3808844d67.jpg)
REPLICATE Dental Technologies PLC (RDT), based in Dublin, Ireland has developed, tested and refined a minimally-invasive, patented medical device for replacing teeth, part of the growing trend toward personalized medicine.
The REPLICATE Immediate Tooth Replacement System disrupts the £38 billion dental market in the UK, USA, EU, South Korea and Japan, currently dominated by three-unit dental bridges (13.2 million units, 7% CAGR) and traditional dental implant screws (3.5 million units, 5% CAGR).
Over the past 5 years, the Company has worked on clinically validating its product at selected sites in Europe but has not widely launched the REPLICATE System as the primary market is the retail dental segment in the U.S., representing approximately 50% of dollars spent globally on dental procedures. RDT filed a 510(k) pre-market notification with the U.S. Food and Drug Administration (FDA) and is awaiting regulatory approval to sell in the U.S.
To date, the Company has raised £17 million from founders, management, business angels, and venture capital firms in the U.S. and Europe. £2.4 million was raised on the German crowd investing platform Companisto.
The Company currently has operations in Berlin, Germany and Dallas, Texas, and underwent a restructuring in 2018, forming RDT as a holding company to prepare for capital market entry on EuroNext.
THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE BY THE COMPANY RAISING FINANCE AS IDENTIFIED ABOVE (THE "COMPANY") IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY AND SUBJECT TO THESE TERMS AND CONDITIONS. CROWDCUBE CAPITAL LTD IS AUTHORISED BY THE FCA AND CARRIES OUT DUE DILIGENCE ON EACH COMPANY THAT LISTS ON CROWDCUBE AS SET OUT HERE.
This investment opportunity is not an offer to the public and is only available to registered members of Crowdcube.com who have qualified and categorised themselves as able to invest. The investment opportunity is not directed at persons located in the United States, Canada or Japan. Any person resident outside the United Kingdom who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict access.
In particular, unless otherwise determined by the Company and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offering of the securities mentioned in such materials (the "Securities") by the Company would be made, or any documentation be sent in or into, the United States, Canada or Japan. There will be no public offering of the Securities in the United States.
In order to access the pitch you must first become a qualifying member of Crowdcube on the basis of your status as either (i) self-certified ‘high net worth investor’, (ii) certified ‘sophisticated investor’, (iii) self-certified as a ‘sophisticated investor’ or (iv) certified as a ‘restricted investor’, in each case in accordance with the FCA’s Conduct of Business Sourcebook Chapter 4.7. Potential investors are encouraged to "cross examine" the Company by interactive due diligence and use of the available online forums to bring the "wisdom of the crowd" to bear. Accessing the pitch also means you agree to Crowdcube’s most recent website terms and conditions and investor terms and conditions, which include Crowdcube's limitation of liability.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Crowdcube’s or the Issuer’s press announcements and this information page do not constitute an offer to sell securities of the Company. Further, it does not constitute a recommendation by the Company, Crowdcube or any other party to sell or buy securities in the Company.
By registering or logging into Crowdcube.com to view the investment opportunity, you certify that you are legally entitled to view the investment opportunities, are an authorised investor and you agree to all applicable terms and conditions on this website, including this disclaimer.
To see the rest of the REPLICATE Dental Technologies pitch, join now.
It’s free, quick and easy.
Already registered? Log in
To see the rest of the REPLICATE Dental Technologies pitch, join now.
It’s free, quick and easy.
/https://files-crowdcube-com.s3.amazonaws.com/files/pitch_pics/original/201903/blob_e99d4b6330627094077d6a7eab99aa77)
